JP6948080B2 - 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 - Google Patents
手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 Download PDFInfo
- Publication number
- JP6948080B2 JP6948080B2 JP2019547371A JP2019547371A JP6948080B2 JP 6948080 B2 JP6948080 B2 JP 6948080B2 JP 2019547371 A JP2019547371 A JP 2019547371A JP 2019547371 A JP2019547371 A JP 2019547371A JP 6948080 B2 JP6948080 B2 JP 6948080B2
- Authority
- JP
- Japan
- Prior art keywords
- hepatocellular carcinoma
- patients
- invasive
- tumor
- microvascularly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465170P | 2017-03-01 | 2017-03-01 | |
| US62/465,170 | 2017-03-01 | ||
| US201762504552P | 2017-05-11 | 2017-05-11 | |
| US62/504,552 | 2017-05-11 | ||
| US201762551770P | 2017-08-29 | 2017-08-29 | |
| US62/551,770 | 2017-08-29 | ||
| PCT/CN2018/077105 WO2018157762A1 (en) | 2017-03-01 | 2018-02-24 | Use of sulfated oligosaccharides in the manufacture of a medicament for treating patients with hepatocellular carcinoma after surgical resection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509035A JP2020509035A (ja) | 2020-03-26 |
| JP2020509035A5 JP2020509035A5 (https=) | 2020-07-09 |
| JP6948080B2 true JP6948080B2 (ja) | 2021-10-13 |
Family
ID=63357147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547371A Active JP6948080B2 (ja) | 2017-03-01 | 2018-02-24 | 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10842804B2 (https=) |
| JP (1) | JP6948080B2 (https=) |
| KR (1) | KR102265159B1 (https=) |
| CN (1) | CN110381953A (https=) |
| TW (1) | TWI693071B (https=) |
| WO (1) | WO2018157762A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113160911A (zh) * | 2021-02-26 | 2021-07-23 | 杭州臻合健康科技有限公司 | 一种用于术前肝功能耐受性分析的评估系统 |
| CN117476246B (zh) * | 2023-12-25 | 2024-04-19 | 福建大数据一级开发有限公司 | 基于多类型复发事件的患者生存分析方法、介质及装置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103788141B (zh) * | 2004-03-04 | 2016-08-17 | 普罗吉恩制药有限公司 | 硫酸化寡聚糖衍生物 |
| KR20140050605A (ko) | 2011-06-09 | 2014-04-29 | 메디젠 바이오테크놀로지 코프 | 간암의 재발, 악화 또는 전이 억제용 의약조성물 |
-
2018
- 2018-02-08 US US15/892,343 patent/US10842804B2/en active Active
- 2018-02-24 JP JP2019547371A patent/JP6948080B2/ja active Active
- 2018-02-24 CN CN201880014397.6A patent/CN110381953A/zh active Pending
- 2018-02-24 WO PCT/CN2018/077105 patent/WO2018157762A1/en not_active Ceased
- 2018-02-24 KR KR1020197028654A patent/KR102265159B1/ko active Active
- 2018-02-26 TW TW107106359A patent/TWI693071B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201840324A (zh) | 2018-11-16 |
| WO2018157762A1 (en) | 2018-09-07 |
| KR102265159B1 (ko) | 2021-06-17 |
| KR20190120339A (ko) | 2019-10-23 |
| JP2020509035A (ja) | 2020-03-26 |
| CN110381953A (zh) | 2019-10-25 |
| US10842804B2 (en) | 2020-11-24 |
| TWI693071B (zh) | 2020-05-11 |
| US20180250317A1 (en) | 2018-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tarantino et al. | Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review | |
| Lu et al. | Perioperative toripalimab plus chemotherapy for patients with resectable non–small cell lung cancer: the neotorch randomized clinical trial | |
| US20250154274A1 (en) | Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment | |
| Cohen et al. | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) | |
| EP3570840B1 (en) | Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer | |
| JP2022518236A (ja) | 進行期固形腫瘍がんに対する治療用ｒｎａおよび抗ｐｄ１抗体 | |
| JP2019503387A (ja) | 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 | |
| Alden et al. | Salvage ipilimumab plus nivolumab after anti-PD-1/PD-L1 therapy in advanced hepatocellular carcinoma | |
| Tu et al. | Case report: a case of sintilimab-induced cystitis/ureteritis and review of sintilimab-related adverse events | |
| Chang et al. | The current management of alveolar soft part sarcomas | |
| Akamatsu et al. | Pembrolizumab plus amrubicin in patients with relapsed SCLC: multi-institutional, single-arm phase 2 study | |
| Wick et al. | Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial | |
| JP6948080B2 (ja) | 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 | |
| Zhang et al. | A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028 | |
| US20260098087A1 (en) | Dosages of emactuzumab | |
| Bozorgmehr et al. | Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415) | |
| KR20240162547A (ko) | 화학요법과 조합하여 항-pd-l1 항체를 사용하여 담도암을 치료하는 방법 | |
| Subudhi | A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC) | |
| TW202529802A (zh) | 胃癌和／或胃食管結合部癌的治療 | |
| Khan et al. | Failure of the PD-1 blocking agent pembrolizumab to benefit a patient with renal squamous cell cancer | |
| Zeng et al. | Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study | |
| Gang et al. | Whether AI+ CDK4/6i+ HP is suitable treatment for three positive metastatic breast cancer patient with renal insufficiency caused by type 2 diabetes | |
| Gouveia et al. | Immunotherapy-Associated Autoimmune Hemolytic Anemia: Two Case Reports and a Literature Review | |
| DEVELOPM | Drug DeveloPment | |
| EA051386B1 (ru) | Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200521 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200521 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200521 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200610 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210719 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210907 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210910 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6948080 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |